

Eleni Gavriilaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6646491/publications.pdf>

Version: 2024-02-01

203
papers

2,964
citations

201385

27
h-index

233125

45
g-index

206
all docs

206
docs citations

206
times ranked

4063
citing authors

#	ARTICLE	IF	CITATIONS
1	A study of endothelial and platelet microvesicles across different hypertension phenotypes. Journal of Human Hypertension, 2022, 36, 561-569.	1.0	9
2	Non-dipping pattern in early-stage diabetes: association with glycemc profile and hemodynamic parameters. Journal of Human Hypertension, 2022, 36, 805-810.	1.0	5
3	Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood, 2022, 139, 3571-3582.	0.6	33
4	Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e233-e240.	0.2	7
5	A non-interventional study of microcirculation dynamics in allogeneic hematopoietic cell transplantation survivors compared to controls: evidence of impaired microvascular response regardless of conventional cardiovascular risk factors. Bone Marrow Transplantation, 2022, 57, 72-77.	1.3	3
6	Genetic prediction of ICU hospitalization and mortality in COVID-19 patients using artificial neural networks. Journal of Cellular and Molecular Medicine, 2022, 26, 1445-1455.	1.6	45
7	Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center. Journal of Clinical Medicine, 2022, 11, 937.	1.0	7
8	Molecular Advances in Preeclampsia and HELLP Syndrome. International Journal of Molecular Sciences, 2022, 23, 3851.	1.8	12
9	Association of Cerebral Oxygenation During Exercise With Target Organ Damage in Middle-Aged Hypertensive and Normotensive Individuals. American Journal of Hypertension, 2022, 35, 664-671.	1.0	2
10	Long COVID-19 of Researchers: What to Do Next?. HemaSphere, 2022, 6, e673.	1.2	5
11	Molecular Advances in Hypertension and Blood. International Journal of Molecular Sciences, 2022, 23, 278.	1.8	0
12	Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, 57, 1183-1186.	1.3	6
13	Blunted cerebral oxygenation during exercise in systemic lupus erythematosus patients.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
14	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. Journal of Clinical Medicine, 2022, 11, 3355.	1.0	4
15	Novel Insights into Factor D Inhibition. International Journal of Molecular Sciences, 2022, 23, 7216.	1.8	8
16	Targeted Genotyping of MIS-C Patients Reveals a Potential Alternative Pathway Mediated Complement Dysregulation during COVID-19 Infection. Current Issues in Molecular Biology, 2022, 44, 2811-2824.	1.0	4
17	Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot. Heliyon, 2022, 8, e09863.	1.4	5
18	Hypertension in rheumatic diseases: prevalence, awareness, treatment, and control rates according to current hypertension guidelines. Journal of Human Hypertension, 2021, 35, 419-427.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Repeated Negative Serological Testing in Otherwise Healthy Patients With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 924-926.	1.9	3
20	Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1138-1143.	1.0	14
21	Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome: Disappearance of cytogenetic abnormalities. <i>Cancer Genetics</i> , 2021, 250-251, 1-5.	0.2	1
22	Complement Inhibition with Eculizumab in Adult Transplant-Associated Thrombotic Microangiopathy: Opening the Pandora's Box. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S270-S271.	0.6	2
23	Toll-Like Receptors in the Pathogenesis of Essential Hypertension. A Forthcoming Immune-Driven Theory in Full Effect. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3451.	1.8	12
24	Complement in Sickle Cell Disease: Are We Ready for Prime Time?. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 177-187.	0.7	8
25	JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature. <i>Thrombosis Journal</i> , 2021, 19, 16.	0.9	5
26	Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients. <i>Clinical Infectious Diseases</i> , 2021, 73, 2073-2082.	2.9	15
27	ASSOCIATION OF HYPERTENSION WITH QUALITY OF LIFE AND MEASURES OF MENTAL AND PHYSICAL HEALTH IN PATIENTS WITH RHEUMATIC DISEASES. <i>Journal of Hypertension</i> , 2021, 39, e194.	0.3	0
28	IN NEWLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS FLOW-MEDIATED DILATATION IS IMPAIRED AND ASSOCIATED INDEPENDENTLY WITH THE DIAGNOSIS OF DIABETES. <i>Journal of Hypertension</i> , 2021, 39, e215.	0.3	0
29	The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD). <i>Journal of Clinical Medicine</i> , 2021, 10, 2050.	1.0	23
30	Genetic justification of severe COVID-19 using a rigorous algorithm. <i>Clinical Immunology</i> , 2021, 226, 108726.	1.4	47
31	Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing. <i>Thrombosis Update</i> , 2021, 3, 100043.	0.4	3
32	Survival Advantage of Treosulfan Plus Fludarabine Before Allogeneic Hematopoietic Cell Transplantation for Older or Comorbid Patients With Myeloid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 916.e1-916.e6.	0.6	5
33	Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. <i>Blood Reviews</i> , 2021, 48, 100805.	2.8	12
34	Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	1.0	8
35	Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. <i>Expert Review of Hematology</i> , 2021, 14, 831-840.	1.0	4
36	Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease. <i>Transplantation Proceedings</i> , 2021, 53, 2261-2266.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship. <i>Thrombosis Update</i> , 2021, 5, 100062.	0.4	5
38	Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation. <i>HemaSphere</i> , 2021, 5, e487.	1.2	22
39	Update on endothelial dysfunction in COVID-19: severe disease, long COVID-19 and pediatric characteristics. <i>Journal of Laboratory Medicine</i> , 2021, 45, 293-302.	1.1	9
40	Chimeric Antigen Receptor T Cells for Refractory/Relapsed Diffuse Large B Cell Lymphoma and Acute Lymphoblastic Leukemia: The Hellenic Real-World Experience in Adult Patients. <i>Blood</i> , 2021, 138, 4840-4840.	0.6	0
41	Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). <i>Blood</i> , 2021, 138, 1787-1787.	0.6	1
42	Identification of Complement-Related Missense Variants in Pediatric Patients with Acute and Post COVID-19 Syndromes. <i>Blood</i> , 2021, 138, 3154-3154.	0.6	0
43	Humoral and T Cell Immune Responses to Sars-Cov-2 Vaccination in Hematopoietic Cell Transplant Recipients. <i>Blood</i> , 2021, 138, 2896-2896.	0.6	1
44	Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. <i>Experimental Hematology and Oncology</i> , 2021, 10, 57.	2.0	14
45	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 613-622.	1.3	15
46	Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: In Search of the Truth. <i>Acta Haematologica</i> , 2020, 143, 405-406.	0.7	3
47	Endothelial Dysfunction in Patients with Rheumatoid Arthritis: the Role of Hypertension. <i>Current Hypertension Reports</i> , 2020, 22, 56.	1.5	24
48	Nighttime dipping status and risk of cardiovascular events in patients with untreated hypertension: A systematic review and meta-analysis. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1951-1959.	1.0	35
49	Thrombocytopenia in COVID-19: pathophysiology matters. <i>Annals of Hematology</i> , 2020, 100, 2139-2140.	0.8	2
50	Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. <i>Pharmaceuticals</i> , 2020, 13, 341.	1.7	15
51	Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses. <i>Current Hypertension Reports</i> , 2020, 22, 63.	1.5	121
52	Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. <i>British Journal of Haematology</i> , 2020, 189, e227-e230.	1.2	160
53	A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3886.	1.8	23
54	Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. <i>European Journal of Cancer</i> , 2020, 130, 1-11.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. <i>Blood</i> , 2020, 135, 239-251.	0.6	145
56	Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy. <i>Thrombosis and Haemostasis</i> , 2020, 120, 638-646.	1.8	33
57	Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Clones: Time for a Change. <i>HemaSphere</i> , 2020, 4, e345.	1.2	2
58	The impact of hyperglycemia on urinary albumin excretion in recent onset diabetes mellitus type II. <i>BMC Nephrology</i> , 2020, 21, 119.	0.8	3
59	Risk Factors and Outcomes of <i>Klebsiella pneumoniae</i> Infection Before and After Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Medicine</i> , 2020, 7, 608165.	1.2	2
60	The Impact of Antibiotic-Mediated Modification of the Intestinal Microbiome on Outcomes of Allogeneic Hematopoietic Cell Transplantation: Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1738-1746.	2.0	24
61	Effect of the COVID-19 Pandemic on Laboratory and Clinical Research: A Testimony and a Call to Action From Researchers. <i>HemaSphere</i> , 2020, 4, e499.	1.2	14
62	Complementopathies and precision medicine. <i>Journal of Clinical Investigation</i> , 2020, 130, 2152-2163.	3.9	70
63	An Update in Drug-Induced Thrombotic Microangiopathy. <i>Frontiers in Medicine</i> , 2020, 7, 212.	1.2	20
64	Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9768.	1.8	11
65	P.65 Increased Biomarkers of Endothelial Dysfunction and Thrombotic Microenvironment in Patients with Autoimmune Rheumatic Disorders Free from Cardiovascular Comorbidities. <i>Artery Research</i> , 2020, 26, S89-S89.	0.3	0
66	Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes. <i>Blood</i> , 2020, 136, 31-31.	0.6	0
67	Allogeneic Hematopoietic Cell Transplantation with Myeloablative Conditioning Regimen of Reduced Toxicity Is Associated with Favorable Survival in Patients with Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
68	Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
69	Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents. <i>Stem Cells International</i> , 2019, 2019, 1-9.	1.2	11
70	Early Prediction of Cardiovascular Risk after Hematopoietic Cell Transplantation: Are We There Yet?. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e310-e316.	2.0	15
71	Endothelial Microvesicles Circulating in Peripheral and Coronary Circulation Are Associated With Central Blood Pressure in Coronary Artery Disease. <i>American Journal of Hypertension</i> , 2019, 32, 1199-1205.	1.0	21
72	Isolated Extramedullary Relapse as a Poor Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1756-1760.	2.0	16

#	ARTICLE	IF	CITATIONS
73	Linking Complement Activation, Coagulation, and Neutrophils in Transplant-Associated Thrombotic Microangiopathy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1433-1440.	1.8	45
74	Neurologic complications after allogeneic transplantation: a meta-analysis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2037-2047.	1.7	13
75	Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease. <i>International Journal of Hematology</i> , 2019, 110, 529-532.	0.7	17
76	Brentuximab vedotin and anti-CD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data. <i>Hematological Oncology</i> , 2019, 37, 490-492.	0.8	1
77	Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality. <i>Journal of Neurology</i> , 2019, 266, 1960-1972.	1.8	15
78	Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 458-465.	0.9	40
79	Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. <i>Frontiers in Immunology</i> , 2019, 10, 337.	2.2	69
80	Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments. <i>Blood Reviews</i> , 2019, 35, 51-58.	2.8	20
81	INTRACARDIAC CIRCULATING PLATELET MICROVESICLES ARE ASSOCIATED WITH THE SEVERITY OF CORONARY ARTERY DISEASE. <i>Journal of Hypertension</i> , 2019, 37, e82.	0.3	1
82	ENDOTHELIAL MICROVESICLES ARE INCREASED IN UNTREATED NEWLY DIAGNOSED HYPERTENSION AND ARE ASSOCIATED WITH URINARY ALBUMIN EXCRETION. <i>Journal of Hypertension</i> , 2019, 37, e151.	0.3	0
83	A STUDY OF MICROVESICLES IN THE ASSESSMENT OF THE THROMBOTIC MICROENVIRONMENT IN NEWLY DIAGNOSED DIABETES MELLITUS TYPE 2. <i>Journal of Hypertension</i> , 2019, 37, e296-e297.	0.3	0
84	BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 921-923.	1.3	5
85	Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis. <i>Clinical Cardiology</i> , 2019, 42, 62-68.	0.7	31
86	Complement-Mediated Coagulation Disorders. , 2019, , 473-490.		0
87	Easix Is Strongly Associated with Complement Activation and Overall Survival in Adult Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Blood</i> , 2019, 134, 4520-4520.	0.6	4
88	Plasmic and Plasice Îre Îxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes. <i>Blood</i> , 2019, 134, 4913-4913.	0.6	2
89	PF693ÂPRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REALÂWORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY. <i>HemaSphere</i> , 2019, 3, 301.	1.2	1
90	PS1529 CROSSTALK AMONG COMPLEMENT, COAGULATION AND NEUTROPHILS IN TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY. <i>HemaSphere</i> , 2019, 3, 705-706.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Spectrum of Neurologic Complications after Allogeneic Hematopoietic Cell Transplantation for Hematologic Diseases in Adults: Systematic Review and Meta-Analysis. <i>Blood</i> , 2019, 134, 5692-5692.	0.6	0
92	Risk Factors and Outcomes of Klebsiella Pneumoniae Infection before and after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 4502-4502.	0.6	0
93	P119 Carotid Stiffness is Strongly Associated with Skin Microvascular Dysfunction in Normotensives and Newly-diagnosed Hypertensives. <i>Artery Research</i> , 2019, 25, S159-S159.	0.3	0
94	Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. <i>Hematology</i> , 2018, 23, 558-566.	0.7	28
95	Donor EBV at the time of hematopoietic cell transplantation: Is it time to adopt molecular assays?. <i>Journal of Clinical Virology</i> , 2018, 102, 32-33.	1.6	3
96	Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes. <i>Journal of Clinical Hypertension</i> , 2018, 20, 680-685.	1.0	21
97	Aldosterone as a mediator of microvascular and macrovascular damage in a population of normotensive to early-stage hypertensive individuals. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 50-57.	2.3	16
98	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	0.8	15
99	Exercise-induced benefits in metabolic syndrome. <i>Journal of Clinical Hypertension</i> , 2018, 20, 19-21.	1.0	2
100	INTRACARDIAC AND PERIPHERAL CIRCULATING ENDOTHELIAL MICROPARTICLES ARE ASSOCIATED WITH CENTRAL SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH CORONARY ARTERY DISEASE. <i>Journal of Hypertension</i> , 2018, 36, e232-e233.	0.3	0
101	ASSOCIATION OF SERUM URIC ACID LEVELS WITH ARTERIAL STIFFNESS AND ENDOTHELIAL DYSFUNCTION IN A POPULATION OF NORMOTENSIVE TO EARLY-STAGE HYPERTENSIVE INDIVIDUALS. <i>Journal of Hypertension</i> , 2018, 36, e95-e96.	0.3	1
102	DETERMINANTS OF URINARY ALBUMIN EXCRETION IN NEWLY DIAGNOSED DIABETES MELLITUS. <i>Journal of Hypertension</i> , 2018, 36, e11.	0.3	0
103	Pre- and Post-transfusion Complement Activation in Transfusion-dependent β^0 -thalassaemia. <i>HemaSphere</i> , 2018, 2, e58.	1.2	5
104	ASSOCIATION OF ENDOTHELIAL DYSFUNCTION IN MICROCIRCULATION USING LASER SPECKLE CONTRAST ANALYSIS WITH MARKERS OF ARTERIAL STIFFNESS. <i>Journal of Hypertension</i> , 2018, 36, e99-e100.	0.3	2
105	Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study. <i>Journal of Clinical Apheresis</i> , 2018, 33, 654-660.	0.7	28
106	Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. <i>Hemoglobin</i> , 2018, 42, 339-341.	0.4	22
107	Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13371.	0.8	48
108	Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. <i>Annals of Hematology</i> , 2018, 97, 1987-1994.	0.8	26

#	ARTICLE	IF	CITATIONS
109	EBV-Related Post-Transplant Lymphoproliferative Disease in Allogeneic Hematopoietic Cell Transplantation: Single-Center Experience and Considerations Regarding CNS Involvement. <i>Blood</i> , 2018, 132, 5706-5706.	0.6	2
110	Disease Risk Index Is Independently Associated with Long-Term Outcomes of Allogeneic Transplantation Post Reduced-Intensity Conditioning in Lymphoid Malignancies. <i>Blood</i> , 2018, 132, 5773-5773.	0.6	0
111	Neurological Adverse Events Determine Morbidity and Mortality Post Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 5732-5732.	0.6	0
112	Pre-Transplant Genetic Susceptibility in Adult Allogeneic Hematopoietic Cell Transplant Recipients: Incidence and Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy. <i>Blood</i> , 2018, 132, 3401-3401.	0.6	0
113	Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry. <i>Blood</i> , 2018, 132, 5463-5463.	0.6	0
114	Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 445-451.	2.0	32
115	<i>Candida</i> is an emerging pathogen beyond the neutropenic period of allogeneic hematopoietic cell transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12921.	0.8	6
116	Beneficial effects of nonpharmacological interventions in the management of essential hypertension. <i>JRSM Cardiovascular Disease</i> , 2017, 6, 204800401668389.	0.4	13
117	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2017, 123, 1965-1970.	2.0	31
118	Donor Lymphocyte Infusions' Efficacy in Relapsed Acute Myeloid Leukemia Post Allogeneic Hematopoietic Cell Transplantation: A Single Center Long-Term Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S375-S376.	2.0	0
119	In Vitro Evidence of Complement Activation in Transplant Associated-Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S244-S245.	2.0	1
120	Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. <i>Haematologica</i> , 2017, 102, 466-475.	1.7	74
121	In vitro evidence of complement activation in patients with sickle cell disease. <i>Haematologica</i> , 2017, 102, e481-e482.	1.7	32
122	Unraveling the Genetics of Transplant-Associated Thrombotic Microangiopathy: Lessons to be Learned. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2013-2014.	2.0	2
123	The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 658-666.	0.2	24
124	Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. <i>Hematological Oncology</i> , 2017, 35, 932-934.	0.8	25
125	In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. <i>Blood Advances</i> , 2017, 1, 1632-1634.	2.5	20
126	A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model. <i>PLoS ONE</i> , 2017, 12, e0174074.	1.1	13

#	ARTICLE	IF	CITATIONS
127	Depression, anxiety, and quality of life in a large cohort of patients with rheumatic diseases: common, yet undertreated. <i>Clinical Rheumatology</i> , 2016, 35, 733-739.	1.0	37
128	Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak. <i>Journal of Clinical & Experimental Nephrology</i> , 2016, 01, .	0.1	20
129	Acquired reactive perforating collagenosis and pseudoporphyric bullous dermatosis in a hemodialysis patient. <i>Hemodialysis International</i> , 2016, 20, E14-E18.	0.4	2
130	PATHWAY-2: spironolactone for resistant hypertension. <i>Lancet, The</i> , 2016, 387, 1372.	6.3	0
131	Understanding cardiovascular risk in hemophilia: A step towards prevention and management. <i>Thrombosis Research</i> , 2016, 140, 14-21.	0.8	15
132	Direct evidence of complement activation in HELLP syndrome: A link to Atypical hemolytic uremic syndrome. <i>Experimental Hematology</i> , 2016, 44, 390-398.	0.2	80
133	Efficacy and Toxicity of Donor Lymphocyte Infusions in Relapsed Acute Myeloid Leukemia Post Allogeneic Hematopoietic Cell Transplantation: Single-Center Experience. <i>Blood</i> , 2016, 128, 5804-5804.	0.6	1
134	Renal manifestations of human brucellosis: First report of minimal change disease. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2016, 27, 590.	0.4	4
135	Ossification of the cervical ligamentum flavum and osseous brown tumor: late manifestations of primary hyperparathyroidism misdiagnosed in a case of parathyroid carcinoma. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016, 13, 54-6.	1.0	6
136	Î2-2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome. <i>Blood</i> , 2016, 128, 3818-3818.	0.6	0
137	Transplant-Associated Thrombotic Microangiopathy: Prevalence, Prognostic Factors and Treatment Outcomes in Unrelated Allogeneic Transplant for Hematologic Diseases. <i>Blood</i> , 2016, 128, 982-982.	0.6	4
138	Allogeneic Hematopoietic Stem Cell Transplantation for Primary Refractory Acute Lymphoblastic Leukemia - a Report from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 4668-4668.	0.6	0
139	Visit-to-Visit Blood Pressure Variability: More to Come. <i>Journal of Clinical Hypertension</i> , 2015, 17, 116-117.	1.0	2
140	Disseminated tuberculosis: A neglected entity in immunocompromised hemodialysis patients. <i>Hemodialysis International</i> , 2015, 19, E8-E11.	0.4	3
141	<sc>B</sc>12 deficiency in chronic kidney disease: early recognition matters. <i>Internal Medicine Journal</i> , 2015, 45, 1195-1196.	0.5	5
142	Unexpected Abscess Localization of the Anterior Abdominal Wall in an ADPKD Patient Undergoing Hemodialysis. <i>Case Reports in Nephrology</i> , 2015, 2015, 1-4.	0.2	0
143	Rare Skeletal Complications in the Setting of Primary Hyperparathyroidism. <i>Case Reports in Endocrinology</i> , 2015, 2015, 1-4.	0.2	3
144	Mental health disorders, but not traditional cardiovascular risk factors, are associated with sexual dysfunction in rheumatologic patients. <i>Atherosclerosis</i> , 2015, 241, e224-e225.	0.4	0

#	ARTICLE	IF	CITATIONS
145	Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 3071-3081.	0.6	16
146	Modified Ham test for atypical hemolytic uremic syndrome. <i>Blood</i> , 2015, 125, 3637-3646.	0.6	88
147	Antiplatelet Treatment in Essential Hypertension: Where Do We Stand?. <i>Current Hypertension Reports</i> , 2015, 17, 536.	1.5	6
148	Platelets Interplay Between Pneumonia and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1487-1488.	1.2	1
149	Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. <i>Infectious Diseases</i> , 2015, 47, 743-746.	1.4	40
150	A prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 1733-1740.	0.8	18
151	Clinical Significance of Endothelial Dysfunction in Essential Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 85.	1.5	88
152	<i>Coxiella burnetii</i> : a new player in atherosclerosis or an innocent bystander?. <i>Clinical Microbiology and Infection</i> , 2015, 21, e29.	2.8	0
153	Mean platelet volume in hypertensive urgencies and emergencies: Opening the Pandora's Box. <i>Platelets</i> , 2015, 26, 275-276.	1.1	1
154	Effects of Acute and Chronic Exercise in Patients With Essential Hypertension: Benefits and Risks. <i>American Journal of Hypertension</i> , 2015, 28, 429-439.	1.0	15
155	Modified Ham Test Distinguishes aHUS from TTP and Predicts Response to Eculizumab. <i>Blood</i> , 2015, 126, 103-103.	0.6	11
156	Small Molecule Factor D Inhibitors Block Complement Activation in Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome. <i>Blood</i> , 2015, 126, 275-275.	0.6	4
157	Survival Advantage with Comparable Complete Chimerism Patterns in Reduced Toxicity Treosulfan-Based Vs Reduced Intensity Busulfan-Based Conditioning Regimen in AML/MDS Patients Undergoing Allogeneic Haematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 1914-1914.	0.6	0
158	The Predictive Significance of Early Metabolic Remission Post Autologous Hematopoietic Transplantation in Lymphomas Conditioned with Either BEAM or a Busulfan-Based Regimen. <i>Blood</i> , 2015, 126, 1984-1984.	0.6	0
159	Direct Evidence of Complement Activation in HELLP Syndrome: A Link to Atypical Hemolytic Uremic Syndrome. <i>Blood</i> , 2015, 126, 1047-1047.	0.6	0
160	The Putative Role of Vitamin D in Essential Hypertension: Stepping Into the Light?. <i>American Journal of Hypertension</i> , 2014, 27, 985-986.	1.0	0
161	Reply To: Seeing the Forest, But Not the Trees: Pertinent Considerations for Examining Acute Changes in Pulse Wave Velocity in Response to Pharmaceutical Interventions and Exercise. <i>Journal of Clinical Hypertension</i> , 2014, 16, 769-769.	1.0	2
162	Exercise-Induced Pulse Wave Velocity Changes in Untreated Patients With Essential Hypertension: The Effect of an Angiotensin Receptor Antagonist. <i>Journal of Clinical Hypertension</i> , 2014, 16, 482-487.	1.0	30

#	ARTICLE	IF	CITATIONS
163	Association Between Cardiotrophin 1 Levels and Central Blood Pressure in Untreated Patients With Essential Hypertension. <i>American Journal of Hypertension</i> , 2014, 27, 651-655.	1.0	13
164	An Uncommon Presentation of Spontaneous Rectus Sheath Hematoma with Acute Kidney Injury due to Obstructive Uropathy and Prerenal Azotemia. <i>Case Reports in Emergency Medicine</i> , 2014, 2014, 1-4.	0.1	5
165	Association Between Mental Health Disorders and Sexual Dysfunction in Patients Suffering from Rheumatic Diseases. <i>Journal of Sexual Medicine</i> , 2014, 11, 2653-2660.	0.3	20
166	Platelet Activation in Essential Hypertension During Exercise: Pre- and Post-Treatment Changes With an Angiotensin II Receptor Blocker. <i>American Journal of Hypertension</i> , 2014, 27, 571-578.	1.0	12
167	Increased thrombotic and impaired fibrinolytic response to acute exercise in patients with essential hypertension: The effect of treatment with an angiotensin II receptor blocker. <i>Journal of Human Hypertension</i> , 2014, 28, 606-609.	1.0	17
168	Association Between Retinal Vessel Caliber and Arterial Stiffness in a Population Comprised of Normotensive To Early-Stage Hypertensive Individuals. <i>American Journal of Hypertension</i> , 2014, 27, 1472-1478.	1.0	61
169	Accumulation of microvascular target organ damage in newly diagnosed hypertensive patients. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 542-549.	2.3	45
170	An exceptional case of renal artery restenosis in a patient with polycythaemia vera. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 904-906.	0.5	3
171	The enigma of microvascular and macrovascular changes in mild essential hypertension. <i>Journal of Hypertension</i> , 2014, 32, 1544.	0.3	1
172	Cardiovascular risk in psoriatic arthritis: should we focus on hypertension and diabetes only?. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 995.	0.4	0
173	Frequency and specificity of antibodies against nuclear and cytoplasmic antigens in healthy individuals by classic and new methods. <i>Clinical Rheumatology</i> , 2013, 32, 1541-1546.	1.0	7
174	The impact of frequently encountered cardiovascular risk factors on sexual dysfunction in rheumatic disorders. <i>Andrology</i> , 2013, 1, 556-562.	1.9	14
175	Splenic infarction as a rare complication of infectious mononucleosis due to Epstein-Barr virus infection in a patient with no significant comorbidity: Case report and review of the literature. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 888-890.	1.5	10
176	Ischemic hepatitis during hemodialysis in a patient with end-stage renal disease. <i>European Journal of Internal Medicine</i> , 2013, 24, e70.	1.0	2
177	Autologous HSCT for systemic sclerosis. <i>Lancet</i> , The, 2013, 381, 2080.	6.3	1
178	Pathogen Burden and Hypertension: More Questions Than Answers. <i>American Journal of Hypertension</i> , 2013, 26, 1459-1459.	1.0	2
179	Letter by Gavriilaki et al Regarding Article, "Bacterial Signatures in Thrombus Aspirates of Patients With Myocardial Infarction". <i>Circulation</i> , 2013, 128, e236.	1.6	0
180	Divergent Retinal Vascular Abnormalities in Normotensive Persons and Patients With Never-Treated, Masked, White Coat Hypertension. <i>American Journal of Hypertension</i> , 2013, 26, 318-325.	1.0	49

#	ARTICLE	IF	CITATIONS
181	More fuel in the obesity paradox debate. <i>International Journal of Obesity</i> , 2013, 37, 320-320.	1.6	2
182	Does Vitamin D Really Contribute to Excess Cardiovascular Risk in Rheumatoid Arthritis? Comment on the Article by Haque et al. <i>Arthritis Care and Research</i> , 2013, 65, 1203-1203.	1.5	0
183	Exercise-induced platelet activation in essential hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1915-1916.	0.3	3
184	Retinopathy Assessment in Hypertension Is Still Puzzling. <i>American Journal of Hypertension</i> , 2012, 25, 726-726.	1.0	1
185	Leiomyosarcoma of Renal Vein, Initially Resembling Pheochromocytoma. <i>Clinical and Experimental Hypertension</i> , 2012, 34, 429-431.	0.5	7
186	Elevated Levels of MMP-9 in Untreated Patients with Stage I Essential Hypertension. <i>Clinical and Experimental Hypertension</i> , 2012, 34, 561-566.	0.5	9
187	Cardiovascular Risk in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 422-430.	0.5	56
188	Clarifying the role of preoperative β -blockade in pheochromocytoma?. <i>Journal of Hypertension</i> , 2012, 30, 1045.	0.3	1
189	P4.34 ARTERIAL STIFFNESS CHANGES DURING ACUTE EXERCISE IN PATIENTS WITH UNTREATED STAGE I ESSENTIAL HYPERTENSION. <i>Artery Research</i> , 2012, 6, 192.	0.3	0
190	Atherosclerosis and infection: is the jury still not in?. <i>Future Microbiology</i> , 2012, 7, 1217-1230.	1.0	22
191	The impact of sexual dysfunction on quality of life in male and female patients with musculoskeletal disorders. <i>Journal of Men's Health</i> , 2011, 8, 218-219.	0.1	0
192	Prevalence of depression in male and female patients with rheumatic disorders. <i>Journal of Men's Health</i> , 2011, 8, 236-237.	0.1	0
193	The effect of depression on quality of life in male and female patients with rheumatic diseases: indications of gender diversity. <i>Journal of Men's Health</i> , 2011, 8, 242-242.	0.1	0
194	Evaluating the True Prevalence of Resistant Hypertension. <i>Hypertension</i> , 2011, 58, e23; author reply e24-5.	1.3	4
195	Hematopoietic cell transplantation and emerging viral infections. <i>Journal of Medical Virology</i> , 2010, 82, 528-538.	2.5	15
196	Platelet Activation in Essential Hypertension: Implications for Antiplatelet Treatment. <i>American Journal of Hypertension</i> , 2010, 23, 229-236.	1.0	65
197	Absence of human bocavirus in atherosclerotic plaques of carotid arteries by real-time polymerase chain reaction. <i>Scandinavian Journal of Infectious Diseases</i> , 2010, 42, 623-625.	1.5	1
198	Seroepidemiology of Chlamydia Pneumoniae in Northern Greece. <i>European Journal of Inflammation</i> , 2009, 7, 139-144.	0.2	2

#	ARTICLE	IF	CITATIONS
199	Neurofibromatosis type 1: should we screen for other genetic syndromes? A case report of coexistence with multiple endocrine neoplasia 2A. <i>European Journal of Clinical Investigation</i> , 2009, 39, 828-832.	1.7	17
200	The pathogenesis of arterial stiffness and its prognostic value in essential hypertension and cardiovascular diseases. <i>Hippokratia</i> , 2009, 13, 70-5.	0.3	26
201	Low Body Mass Index Is an Independent Risk Factor for Transplant-Associated Microangiopathy following Total-Body Irradiation-Based Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1076-1078.	2.0	8
202	Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation. <i>Thrombosis Research</i> , 2006, 118, 611-618.	0.8	16
203	Blunted cerebral oxygenation during exercise in systemic lupus erythematosus patients. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0